Literature DB >> 3844370

Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.

F Kievits, A Kijlstra.   

Abstract

In the study described here, the effect of human tears and purified lactoferrin was investigated on the deposition of complement components on solid-phase bound immune complexes. After incubating immune complexes with fresh normal human serum, the deposition of complement components (C3, C4 and C5) was measured with an ELISA technique. Rabbit antibodies were used as a constituent of the immune complexes, and so both alternative and classical complement pathway activation could be studied. The addition of human tears or purified lactoferrin to this system resulted in the inhibition of classical pathway deposition of C3 and C5, while C4 deposition was not affected. High concentrations of human tears also inhibited alternative pathway C3 deposition on immune complexes, whereas lactoferrin did not detectably affect this pathway. The inhibition of complement activation by tears was not due to a masking of the immune complexes or the already deposited C3. Experiments with purified lactoferrin furthermore showed that lactoferrin did not bind to the complexes, either before or during complement activation. These findings suggest that the complement inhibitory effect is probably taking place in the fluid phase. Saturation of lactoferrin with iron or copper ions resulted in a markedly diminished effect on the capacity of lactoferrin to inhibit complement activation. C4 deposition on immune complexes was not affected by lactoferrin, which suggested that the inhibition of the classical pathway was due to an effect on the classical C3 convertase. The fact that lactoferrin inhibits the classical, but not the alternative C3 convertase, suggests that the effect is probably not mediated through a competition for certain trace metal ions, but may be caused by protein-protein interactions. The findings reported here indicate that lactoferrin may play an important anti-inflammatory role by modulating activation of the complement system. This observation adds a new property to the already described functions of the iron-binding protein lactoferrin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3844370      PMCID: PMC1453535     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  16 in total

1.  Association of lactoferrin with other proteins, as demonstrated by changes in electrophoretic mobility.

Authors:  A Hekman
Journal:  Biochim Biophys Acta       Date:  1971-12-28

2.  Comparative circular dichroism studies of iron-free and iron-saturated forms of human serotransferrin and lactortransferrin.

Authors:  J Mazurier; J P Aubert; M H Loucheux-Lefevre
Journal:  FEBS Lett       Date:  1976-07-15       Impact factor: 4.124

3.  Hemolytic complement in tears.

Authors:  B J Mondino; G W Zaidman
Journal:  Ophthalmic Res       Date:  1983       Impact factor: 2.892

4.  Lactoferrin binding to human peripheral blood cells: an interaction with a B-enriched population of lymphocytes and a subpopulation of adherent mononuclear cells.

Authors:  R M Bennett; J Davis
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

Review 5.  Clinical biochemistry of tears.

Authors:  N J Van Haeringen
Journal:  Surv Ophthalmol       Date:  1981 Sep-Oct       Impact factor: 6.048

6.  The effect of an anticomplementary factor on normal human tears.

Authors:  A Kijlstra; R Veerhuis
Journal:  Am J Ophthalmol       Date:  1981-07       Impact factor: 5.258

7.  Iron-binding proteins in milk and resistance to Escherichia coli infection in infants.

Authors:  J J Bullen; H J Rogers; L Leigh
Journal:  Br Med J       Date:  1972-01-08

8.  Studies on human lactoferrin by electron paramagnetic resonance, fluorescence, and resonance Raman spectroscopy.

Authors:  E W Ainscough; A M Brodie; J E Plowman; S J Bloor; J S Loehr; T M Loehr
Journal:  Biochemistry       Date:  1980-08-19       Impact factor: 3.162

9.  The binding of human lactoferrin to mouse peritoneal cells.

Authors:  J L Van Snick; P L Masson
Journal:  J Exp Med       Date:  1976-12-01       Impact factor: 14.307

10.  Lactoferrin, an iron-binding protein in neutrophilic leukocytes.

Authors:  P L Masson; J F Heremans; E Schonne
Journal:  J Exp Med       Date:  1969-09-01       Impact factor: 14.307

View more
  8 in total

1.  Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.

Authors:  Bing Ren; Alexander J Szalai; Orlanda Thomas; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

2.  Anti-lactoferrin antibodies in systemic lupus erythematosus: isotypes and clinical correlates.

Authors:  Domenico Caccavo; Amelia Rigon; Antonio Picardi; Sara Galluzzo; Marta Vadacca; Giovanni Maria Ferri; Antonio Amoroso; Antonella Afeltra
Journal:  Clin Rheumatol       Date:  2004-12-09       Impact factor: 2.980

3.  Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease.

Authors:  E Peen; S Almer; G Bodemar; B O Rydén; C Sjölin; K Tejle; T Skogh
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

4.  Characterization of binding of human lactoferrin to pneumococcal surface protein A.

Authors:  A Håkansson; H Roche; S Mirza; L S McDaniel; A Brooks-Walter; D E Briles
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

5.  Activation of the classical pathway of complement by binding of bovine lactoferrin to unencapsulated Streptococcus agalactiae.

Authors:  P Rainard
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

6.  Expression and localization of lactotransferrin messenger RNA in the cortex of Alzheimer's disease.

Authors:  Li An; Haruhisha Sato; Yoshihiro Konishi; Douglas G Walker; Thomas G Beach; Joseph Rogers; Ikuo Tooyama
Journal:  Neurosci Lett       Date:  2009-02-04       Impact factor: 3.046

Review 7.  Lactoferrin in a Context of Inflammation-Induced Pathology.

Authors:  Marian L Kruzel; Michal Zimecki; Jeffrey K Actor
Journal:  Front Immunol       Date:  2017-11-06       Impact factor: 7.561

8.  Local Activation of the Alternative Pathway of Complement System in Mycotic Keratitis Patient Tear.

Authors:  Mohammed Razeeth Shait Mohammed; Sandhya Krishnan; Rabbind Singh Amrathlal; Jeya Maheshwari Jayapal; Venkatesh Prajna Namperumalsamy; Lalitha Prajna; Dharmalingam Kuppamuthu
Journal:  Front Cell Infect Microbiol       Date:  2020-05-06       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.